MA31923B1 - Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes - Google Patents
Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunesInfo
- Publication number
- MA31923B1 MA31923B1 MA32925A MA32925A MA31923B1 MA 31923 B1 MA31923 B1 MA 31923B1 MA 32925 A MA32925 A MA 32925A MA 32925 A MA32925 A MA 32925A MA 31923 B1 MA31923 B1 MA 31923B1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- treatment
- formula
- pharmaceutically acceptable
- autoimmune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention porte sur de nouveaux dérivés d'oxadiazoles représentés par la formule (i) ou sur un sel pharmaceutiquement acceptable de ceux-ci. Les composés représentés par la formule (i) et leurs sels pharmaceutiquement acceptables sont utiles dans le traitement d'états ou de troubles qui sont à médiation par le récepteur s1p1. En particulier, les composés représentés par la formule (i) et leurs sels pharmaceutiquement acceptables sont utiles dans le traitement de la sclérose en plaque, de maladies auto-immunes, de troubles inflammatoires chroniques, de l'asthme, de neuropathies inflammatoires, de l'arthrite, d'une transplantation, de la maladie de crohn, de la rectocolite hémorragique, d'un lupus érythémateux, du psoriasis, d'une lésion d'ischémie-reperfusion, de tumeurs solides et d'une métastase tumorale, de maladies associées à l'angiogénèse, de maladies vasculaires, d'états pathologiques douloureux, de maladies virales aiguës, d'affections intestinales inflammatoires, du diabète insulinodépendant et non insulinodépendant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0725102.8A GB0725102D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
PCT/EP2008/067972 WO2009080730A1 (fr) | 2007-12-21 | 2008-12-19 | Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31923B1 true MA31923B1 (fr) | 2010-12-01 |
Family
ID=39048652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32925A MA31923B1 (fr) | 2007-12-21 | 2010-06-16 | Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100273770A1 (fr) |
EP (1) | EP2220077A1 (fr) |
JP (1) | JP2011506572A (fr) |
KR (1) | KR20100108567A (fr) |
CN (1) | CN101945865A (fr) |
AU (1) | AU2008339993A1 (fr) |
BR (1) | BRPI0821696A2 (fr) |
CA (1) | CA2710055A1 (fr) |
CO (1) | CO6290674A2 (fr) |
CR (1) | CR11576A (fr) |
DO (1) | DOP2010000193A (fr) |
EA (1) | EA017669B1 (fr) |
GB (1) | GB0725102D0 (fr) |
IL (1) | IL206277A0 (fr) |
MA (1) | MA31923B1 (fr) |
NZ (1) | NZ585995A (fr) |
UA (1) | UA101348C2 (fr) |
WO (1) | WO2009080730A1 (fr) |
ZA (1) | ZA201003965B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2012019076A1 (fr) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions et méthodes de traitement prophylactique ou thérapeutique d'une lésion d'ischémie/reperfusion cardiaque |
EP2511275A1 (fr) * | 2011-04-12 | 2012-10-17 | Bioprojet | Nouveaux acides pipéridiniles monocarboxyliques comme agonistes du récepteur S1P1 |
UA114915C2 (uk) | 2012-07-02 | 2017-08-28 | Монсанто Текнолоджи Ллс | Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти) |
CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1670463A2 (fr) * | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 1,2,4-oxadiazoles substitues 3,5-aryle, heteroaryle ou cycloalkyle servant d'agonistes du recepteur s1p |
AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
WO2006047195A2 (fr) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p |
AU2006256968A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands |
MX356221B (es) * | 2006-04-03 | 2018-05-18 | Astellas Pharma Inc | Heterocompuesto. |
PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
-
2007
- 2007-12-21 GB GBGB0725102.8A patent/GB0725102D0/en not_active Ceased
-
2008
- 2008-12-19 BR BRPI0821696-7A patent/BRPI0821696A2/pt not_active IP Right Cessation
- 2008-12-19 CA CA2710055A patent/CA2710055A1/fr not_active Abandoned
- 2008-12-19 CN CN2008801273545A patent/CN101945865A/zh active Pending
- 2008-12-19 NZ NZ585995A patent/NZ585995A/xx not_active IP Right Cessation
- 2008-12-19 EP EP08863729A patent/EP2220077A1/fr not_active Withdrawn
- 2008-12-19 US US12/747,198 patent/US20100273770A1/en not_active Abandoned
- 2008-12-19 WO PCT/EP2008/067972 patent/WO2009080730A1/fr active Application Filing
- 2008-12-19 KR KR1020107016168A patent/KR20100108567A/ko not_active Application Discontinuation
- 2008-12-19 JP JP2010538744A patent/JP2011506572A/ja active Pending
- 2008-12-19 EA EA201070783A patent/EA017669B1/ru not_active IP Right Cessation
- 2008-12-19 AU AU2008339993A patent/AU2008339993A1/en not_active Abandoned
- 2008-12-19 UA UAA201009201A patent/UA101348C2/ru unknown
-
2010
- 2010-06-03 ZA ZA2010/03965A patent/ZA201003965B/en unknown
- 2010-06-10 IL IL206277A patent/IL206277A0/en unknown
- 2010-06-16 MA MA32925A patent/MA31923B1/fr unknown
- 2010-06-21 CO CO10074469A patent/CO6290674A2/es not_active Application Discontinuation
- 2010-06-21 DO DO2010000193A patent/DOP2010000193A/es unknown
- 2010-07-21 CR CR11576A patent/CR11576A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB0725102D0 (en) | 2008-01-30 |
WO2009080730A1 (fr) | 2009-07-02 |
IL206277A0 (en) | 2010-12-30 |
CN101945865A (zh) | 2011-01-12 |
BRPI0821696A2 (pt) | 2015-06-16 |
DOP2010000193A (es) | 2010-08-15 |
CA2710055A1 (fr) | 2009-07-02 |
UA101348C2 (ru) | 2013-03-25 |
ZA201003965B (en) | 2011-03-30 |
KR20100108567A (ko) | 2010-10-07 |
EA201070783A1 (ru) | 2010-12-30 |
NZ585995A (en) | 2012-12-21 |
US20100273770A1 (en) | 2010-10-28 |
JP2011506572A (ja) | 2011-03-03 |
CO6290674A2 (es) | 2011-06-20 |
CR11576A (es) | 2010-09-03 |
EP2220077A1 (fr) | 2010-08-25 |
EA017669B1 (ru) | 2013-02-28 |
AU2008339993A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31923B1 (fr) | Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes | |
EP3658538A1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp | |
US8796247B2 (en) | Indole derivative, and pharmacologically acceptable salt thereof | |
MA31504B1 (fr) | Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes | |
CA2832377C (fr) | Composes de pyridazinone et de pyridone | |
TW201121544A (en) | Novel phenol derivative | |
WO2004101529A1 (fr) | Compose heterocyclique azote et son utilisation medicale | |
US20120122931A1 (en) | Indole derivative or pharmaceutically acceptable salt thereof | |
WO2017086430A1 (fr) | Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash) | |
NZ594244A (en) | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | |
JP6755950B2 (ja) | ラクタム化合物誘導体およびその応用 | |
TW200925154A (en) | Phenylacetic acid compound | |
US8222274B2 (en) | Pyrrole derivative or salt thereof | |
JP6033791B2 (ja) | 新規s1p受容体調整薬 | |
KR20230048361A (ko) | 만성 신장 질환의 치료 방법 | |
JP7511060B2 (ja) | ペルオキシソーム増殖剤応答性受容体活性化剤 | |
JP2021127289A (ja) | 縮合ピリミジン誘導体 | |
MA32473B1 (fr) | Dérivés de 5-(4-méthanesulfonyl-phényl)-thiazole pour le traitement de maladies inflammatoires aiguës et chroniques | |
MA56324B1 (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
JP7185226B2 (ja) | 1,5-アンヒドロフルクトース誘導体を含むampk活性化剤 | |
JP5028594B2 (ja) | LXRα受容体特異的部分アゴニスト | |
JPWO2006104172A1 (ja) | 関節リウマチの予防及び/又は治療薬 | |
US20220009909A1 (en) | Adamts inhibitors, preparation methods and medicinal uses thereof | |
WO1997047604A1 (fr) | Derives de 5-phenyl-3-pyridazinone et compositions medicamenteuses les contenant | |
MA30951B1 (fr) | Medicament pour l'amelioration d'une fonction cognitive et la neuroprotection |